Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of two new drugs pemetrexed
(Alimta) and bevacizumab (Avastin) can increase the effectiveness of treatment for head and
neck cancer. Currently pemetrexed is approved by the Food and Drug Administration (FDA) for
another type of cancer, mesothelioma, but it is not approved for head and neck cancer.